Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D

Insulin icodec* (icodec) is a novel once-weekly basal insulin analog in development. This post hoc analysis explored hypoglycemia duration using double-blinded CGM (Dexcom G6 ® ) data from 2 phase 2, randomized, open-label, treat-to-target 16-week trials. One trial compared 3 titration algorithms of...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of endocrinology and metabolism 2022-03, Vol.26 (Suppl 1), p.S7-S7
Main Authors: Manjunath, Aparna, Silver, Robert J, Asong, Marisse, Begtrup, Kamilla, Koefoed, Mette M, Heller, Simon R, Rosenstock, Julio
Format: Article
Language:English
Subjects:
Abstracts … Esicon 2021
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Insulin icodec* (icodec) is a novel once-weekly basal insulin analog in development. This post hoc analysis explored hypoglycemia duration using double-blinded CGM (Dexcom G6 ® ) data from 2 phase 2, randomized, open-label, treat-to-target 16-week trials. One trial compared 3 titration algorithms of icodec vs. insulin glargine U100 (IGlar U100) in 205 insulin-naïve patients with T2D (NCT03951805), the other assessed 154 basal insulin-treated patients with T2D switching from any daily basal insulin to icodec with or without a 100% loading dose vs. IGlar U100 (NCT03922750). In line with ATTD guidelines, a hypoglycemic episode was defined as a CGM period of interstitial glucose (IG)
ISSN:2230-9500
2230-8210
2230-8210
2230-9500
DOI:10.4103/2230-8210.342306